| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-02-26 |
| タイトル |
|
|
タイトル |
Magnetic resonance imaging-based risk factors of hepatocellular carcinoma after direct-acting antiviral therapy: A multicenter observational study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
liver |
| キーワード |
|
|
主題 |
hepatitis C |
| キーワード |
|
|
主題 |
hepatocellular carcinoma |
| キーワード |
|
|
主題 |
magnetic resonance imaging |
| キーワード |
|
|
主題 |
risk factors |
| キーワード |
|
|
主題 |
arterial phase hyperenhancement |
| キーワード |
|
|
主題 |
direct-acting antiviral therapy |
| キーワード |
|
|
主題 |
hepatobiliary phase |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| その他のタイトル |
|
|
その他のタイトル |
Risk factors of HCC after DAA therapy |
| 著者 |
Ichikawa, Shintaro
Motosugi, Utaroh
Sawai, Yoshiyuki
Ishida, Hisashi
Imai, Yasuharu
Kozaka, Kazuto
Tsurusaki, Masakatsu
Sofue, Keitaro
Murakami, Takamichi
Kawai, Nobuyuki
Matsuo, Masayuki
Fukukura, Yoshihiko
Mawatari, Seiichi
Shimizu, Tatsuya
Morisaka, Hiroyuki
Inoue, Taisuke
Goshima, Satoshi
|
| 書誌情報 |
en : Hepatology Research
巻 54,
号 1,
p. 43-53,
発行日 2024-01-06
|
| 出版者 |
|
|
出版者 |
John Wiley and Sons |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
日本肝臓学会 = The Japan Society of Hepatology |
|
言語 |
ja |
| 権利 |
|
|
権利情報 |
This is the peer reviewed version of the following article: "Magnetic resonance imaging-based risk factors of hepatocellular carcinoma after direct-acting antiviral therapy: A multicenter observational study", 54(1), pp43-53, 2024, which has been published in final form at https://doi.org/10.1111/hepr.13964. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited. |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Aim: To determine risk factors associated with hepatocellular carcinoma (HCC) development following direct-acting antiviral (DAA) therapy.
Methods: We enrolled patients with chronic hepatitis C who underwent DAA therapy and achieved sustained virologic response at 12 weeks between 2012 and 2018. Subsequently, patients were followed up. The primary endpoint was the development of HCC or the date of the last follow-up when the absence of HCC was confirmed. Uni- and multi-variate Cox proportional hazard models were used to identify factors contributing to HCC development, including gadoxetic acid-enhanced magnetic resonance imaging findings. The cumulative incidence rates of HCC development were calculated using the Kaplan–Meier method and differences between groups were assessed using the log-rank test.
Results: The final study cohort comprised 482 patients (median age, 70.5 years; 242 men). The median follow-up period was 36.8 months. Among 482 patients, 96 developed HCC (19.9%). The 1-, 3-, and 5-year cumulative rates of HCC development were 4.9%, 18.6%, and 30.5%, respectively. Multivariate analysis revealed that age, male sex, history of HCC, and hepatobiliary phase (HBP) hypointense nodules without arterial phase hyperenhancement (APHE) were independent risk factors significantly associated with HCC development (P<0.001–0.04). The highest risk group included patients with both a history of HCC and the presence of HBP hypointense nodules without APHE (the 1- and 3-year cumulative HCC development rates were 14.2% and 62.2%, respectively).
Conclusion: History of HCC and presence of HBP hypointense nodules without APHE were strong risk factors for HCC development following DAA therapy. |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
1386-6346 |
| EISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1872-034X |
| NII書誌ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11140867 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
37676063 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/hepr.13964 |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
Hepatol Res-54-43.pdf (10.6 MB)
